ReviewTherapeutic advances in medical oncology2022
Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives.
Review in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Giant primary retroperitoneal myxofibrosarcoma mimicking myxoid liposarcoma: a diagnostic and surgical challenge.Journal of surgical case reports · 2026Article
- Infraorbital myxofibrosarcoma: Imaging features and surgical management of a rare facial case.Radiology case reports · 2026Article
- Assessment of infiltrative margins in subcutaneous soft-tissue sarcomas using ultrasonography and gadolinium-enhanced fat-suppressed T1-weighted imaging.Surgery open science · 2026Article
- Gene Expression Profiling ofJournal of clinical practice and research · 2026Article
- Navigating the Role of Radiotherapy for Extremity Soft Tissue Sarcomas.Biomedicines · 2026Review
- Evolution of Recurrent Myxofibrosarcoma of the Thoracic Wall at Single-Cell Resolution: A Case Report.International journal of molecular sciences · 2026Article
- How much is enough? Defining the critical resection margin in myxofibrosarcoma.World journal of surgical oncology · 2026Article
- Culture-dependent baseline states and drug response programs in myxofibrosarcoma models across 2D and 3D systems.Human cell · 2026Article
- AI-derived CT morphometric phenotypes predict survival, functional decline, and surgical morbidity following curative-intent surgical sarcoma resection.Journal of orthopaedic surgery and research · 2026Article
- A CAM bioimaging model reveals the connection between VEGFA vascular remodeling and enhanced sarcoma progression via tumor secretome.Scientific reports · 2026Article
- Early recurrence of left atrial myxofibrosarcoma: A case report of a clinical and histopathologic challenge.Journal of cardiothoracic surgery · 2026Article
- Integrated diagnostic evaluation of multiple malignant neoplasms viaOncology letters · 2026Article
- Primary cardiac myxofibrosarcoma: a case description and literature review of a highly rare entity.Quantitative imaging in medicine and surgery · 2026Article
- An Extensive Tail Sign in Primary Thoracic Myxofibrosarcoma: A Case Report.Surgical case reports · 2026Article
- Recurrent primary intracranial myxofibrosarcoma: a case report and review of the literature.Frontiers in oncology · 2026Article
- Reconstruction with a Custom-made 3D-printed Prosthesis for Limb Salvage and Joint Preservation after Resection of the Calf Myxofibrosarcoma Involving the Tibia: A Case Report and Literature Review.Current medical imaging · 2026Review
- Acute kidney injury predicts mortality, sarcopenia and postoperative morbidity in myxofibrosarcoma patients undergoing surgical resection.World journal of surgical oncology · 2025Article
- Staged Reconstruction Is Not Necessary Following Oncologic Resection of Superficial Myxofibrosarcoma.Cancers · 2025Article
- Impact of resection margins on local recurrence in patients with myxofibrosarcoma.Scientific reports · 2025Article
- A Ten-Step Surgical Approach to Radical Excision of a Primary Ischiorectal Fossa Tumor With IGAP V-Y Flap Reconstruction-A Case Report of a Rare Myxofibrosarcoma.Clinical case reports · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxofibrosarcoma (MFS) is a common entity of adult soft tissue sarcomas (STS) characterized by a predilection of the extremities and a high local recurrence rate. Originally classified as a myxoid variant of malignant fibrous histiocytoma, this musculoskeletal tumor has been recognized since 2002 as a distinct histotype showing a spectrum of malignant fibroblastic lesions with myxoid stroma, pleomorphism and curvilinear vessels. Currently, the molecular pathogenesis of MFS is still poorly understood and its genomic profile exhibits a complex karyotype with a number of aberrations including amplifications, deletions and loss of function. The diagnosis is challenging due to the unavailability of specific immunohistochemical markers and is based on the analysis of cytomorphologic features. The mainstay of treatment for localized disease is represented by surgical resection, with (neo)-adjuvant radio- and chemotherapy. In the metastatic setting, chemotherapy represents the backbone of treatments, however its role is still controversial and the outcome is very poor. Recent advent of genomic profiling, targeted therapies and larger enrollment of patients in translational and clinical studies, have improved the understanding of biological behavior and clinical outcome of such a disease. This review will provide an overview of current diagnostic pitfalls and clinical management of MFS. Finally, a look at future directions will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.